SCHEMBL6301580

SCHEMBL6301580

N[C@@H](CCC(=O)O)C(=O)c1cccc(Sc2ccc3c(c2)OCC(=O)N3)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
RXFP1 Q9HBX9 1/20 0.39
GAA P10253 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP19A1 P11511 2/20 0.37
NSD2 O96028 2/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD3 P35462 1/20 0.36
ALDH1A1 P00352 4/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
PKM P14618 1/20 0.34
KIF11 P52732 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6301560 0.91 ALDH1A1 (0.39) MAPTRXFP1GAANSD2DRD2
SCHEMBL6295486 0.82 MAPT (0.38) MAPTRXFP1GAANSD2DRD2
SCHEMBL6301733 0.75 DRD2 (0.49) MAPTRXFP1GAANSD2DRD2
SCHEMBL6295828 0.73 CYP11B1 (0.44) MAPTNSD2DRD2DRD4DRD3
SCHEMBL6296965 0.70 CYP11B1 (0.44) MAPTGAANSD2DRD2DRD4
SCHEMBL6297460 0.70 CYP11B1 (0.44) MAPTCYP3A4NSD2DRD2DRD4
SCHEMBL6295473 0.69 CYP11B1 (0.43) MAPTGAACYP1A2CYP3A4CYP19A1
SCHEMBL7343583 0.67 ALDH1A1 (0.46) MAPTRXFP1GAANSD2DRD2
SCHEMBL6329957 0.66 DRD4 (0.53) MAPTDRD2DRD4DRD3ALDH1A1
SCHEMBL6717655 0.66 DRD4 (0.50) MAPTNSD2DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951855-B2 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2005-10-04 US disclosed
US-20040122006-A1 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2004-06-24 US disclosed
EP-1385835-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS Astrazeneca AB (SE) 2004-02-04 EP disclosed
WO-2002085868-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS ASTRAZENECA AB (SE) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122006-A1 Benzoxazinone derivatives for use in the treatment of angiogenesis HAX1, VEGFA, HYOU1 MAPT 4831/4885RXFP1 90/4885GAA 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.